NASDAQ:ALKS Alkermes (ALKS) Stock Price, News & Analysis $24.29 +0.06 (+0.25%) (As of 07/5/2024 ET) Add Compare Share Share Today's Range$24.14▼$24.4550-Day Range$23.21▼$25.0552-Week Range$22.01▼$32.88Volume789,495 shsAverage Volume1.76 million shsMarket Capitalization$4.11 billionP/E Ratio9.60Dividend YieldN/APrice Target$36.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Alkermes alerts: Email Address Alkermes MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.55 Rating ScoreUpside/Downside50.3% Upside$36.50 Price TargetShort InterestBearish7.07% of Shares Sold ShortDividend StrengthN/ASustainability-1.17Upright™ Environmental ScoreNews Sentiment1.18Based on 2 Articles This WeekInsider TradingN/AProj. Earnings Growth-7.49%From $2.27 to $2.10 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.42 out of 5 starsMedical Sector96th out of 879 stocksPharmaceutical Preparations Industry29th out of 418 stocks 3.3 Analyst's Opinion Consensus RatingAlkermes has received a consensus rating of Moderate Buy. The company's average rating score is 2.55, and is based on 7 buy ratings, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageAlkermes has only been the subject of 4 research reports in the past 90 days.Read more about Alkermes' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.07% of the outstanding shares of Alkermes have been sold short.Short Interest Ratio / Days to CoverAlkermes has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in Alkermes has recently increased by 1.96%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAlkermes does not currently pay a dividend.Dividend GrowthAlkermes does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAlkermes has received a 60.90% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for physical health", "Antipsychotics", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Alkermes is -1.17. Previous Next 3.4 News and Social Media Coverage News SentimentAlkermes has a news sentiment score of 1.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Alkermes this week, compared to 6 articles on an average week.Search Interest1 people have searched for ALKS on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Alkermes to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alkermes insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.89% of the stock of Alkermes is held by insiders.Percentage Held by Institutions95.21% of the stock of Alkermes is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Alkermes' insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Alkermes are expected to decrease by -7.49% in the coming year, from $2.27 to $2.10 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alkermes is 9.60, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 121.26.Price to Earnings Ratio vs. SectorThe P/E ratio of Alkermes is 9.60, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 96.23.Price to Earnings Growth RatioAlkermes has a PEG Ratio of 0.49. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioAlkermes has a P/B Ratio of 3.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Alkermes' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsTiny Defense Firm Set for Huge Gains with New US ContractOne tiny defense firm just won a groundbreaking US military contract… That could hand early investors gains of up to 35,960%.Click here for the ticker>>> About Alkermes Stock (NASDAQ:ALKS)Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Read More ALKS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALKS Stock News HeadlinesJune 28, 2024 | americanbankingnews.comQ1 2025 EPS Estimates for Alkermes plc Increased by Zacks Research (NASDAQ:ALKS)June 28, 2024 | americanbankingnews.comZacks Research Weighs in on Alkermes plc's Q4 2025 Earnings (NASDAQ:ALKS)July 6, 2024 | Behind the Markets (Ad)Tiny Defense Firm Set for Huge Gains with New US ContractOne tiny defense firm just won a groundbreaking US military contract… That could hand early investors gains of up to 35,960%.June 3, 2024 | prnewswire.comAlkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024May 29, 2024 | prnewswire.comAlkermes to Participate in Two Upcoming Investor ConferencesMay 28, 2024 | finanznachrichten.deAlkermes plc: Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024May 28, 2024 | prnewswire.comAlkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024May 25, 2024 | investorplace.com3 Biotech Stocks That Could Be Millionaire-Makers: May EditionJuly 6, 2024 | Behind the Markets (Ad)Tiny Defense Firm Set for Huge Gains with New US ContractOne tiny defense firm just won a groundbreaking US military contract… That could hand early investors gains of up to 35,960%.May 23, 2024 | markets.businessinsider.com6 Analysts Assess Alkermes: What You Need To KnowMay 21, 2024 | finance.yahoo.comDo Options Traders Know Something About Alkermes (ALKS) Stock We Don't?May 17, 2024 | seekingalpha.comThe Bottom Fishing Club: Alkermes Has Great Value And SafetyMay 14, 2024 | prnewswire.comAlkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific ConferencesMay 3, 2024 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Hold Rating on Alkermes (ALKS)May 2, 2024 | markets.businessinsider.comAlkermes Buy Rating Affirmed on Strong Commercial Performance and Promising Drug PipelineMay 2, 2024 | markets.businessinsider.com7 Analysts Assess Alkermes: What You Need To KnowMay 2, 2024 | markets.businessinsider.comMaintaining Hold on Alkermes Amidst Modest Q1 Performance and Pipeline ProspectsMay 2, 2024 | markets.businessinsider.comAlkermes Hold Rating Justified by Mixed Financial Performance and Uncertain Pipeline ProspectsSee More Headlines Receive ALKS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2024Today7/06/2024Next Earnings (Estimated)7/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:ALKS CUSIPG0176710 CIK1520262 Webwww.alkermes.com Phone(531) 772-8000Fax781-890-0524Employees2,100Year Founded1987Price Target and Rating Average Stock Price Target$36.50 High Stock Price Target$50.00 Low Stock Price Target$25.00 Potential Upside/Downside+50.3%Consensus RatingModerate Buy Rating Score (0-4)2.55 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)$2.53 Trailing P/E Ratio9.60 Forward P/E Ratio10.70 P/E Growth0.49Net Income$355.76 million Net Margins25.17% Pretax Margin27.79% Return on Equity20.31% Return on Assets11.85% Debt Debt-to-Equity Ratio0.23 Current Ratio3.20 Quick Ratio2.77 Sales & Book Value Annual Sales$1.66 billion Price / Sales2.47 Cash Flow$2.27 per share Price / Cash Flow10.68 Book Value$7.21 per share Price / Book3.37Miscellaneous Outstanding Shares169,220,000Free Float160,946,000Market Cap$4.11 billion OptionableOptionable Beta0.47 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Richard F. Pops (Age 62)Chairman & CEO Comp: $2.61MMr. Blair C. Jackson (Age 51)Interim Principal Financial Officer, Executive VP, Chief Risk Officer & COO Comp: $1.17MMr. David Joseph Gaffin (Age 52)Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary Comp: $1.15MMr. Iain Michael Brown (Age 55)Senior VP & CFO (Leave of Absence) Comp: $950.88kDr. Craig C. Hopkinson M.D. (Age 56)Executive VP of Research & Development and Chief Medical Officer Comp: $1.24MDr. Floyd E. Bloom M.D. (Age 87)Founder Comp: $57.73kMr. Samuel J. Parisi (Age 49)Interim Principal Accounting Officer & VP of Finance Mr. Thomas HarveyChief Information Officer & Senior VP of ITMs. Sandra CoombsSenior Vice President of Corporate Affairs & Investor RelationsMr. Stephen SchiavoSenior Vice President of Human ResourcesMore ExecutivesKey CompetitorsEidos TherapeuticsNASDAQ:EIDXAgios PharmaceuticalsNASDAQ:AGIOPacira BioSciencesNASDAQ:PCRXALX OncologyNASDAQ:ALXOAtea PharmaceuticalsNASDAQ:AVIRView All CompetitorsInsiders & InstitutionsGAMMA Investing LLCBought 703 shares on 7/2/2024Ownership: 0.001%Teachers Retirement System of The State of KentuckyBought 45,903 shares on 5/28/2024Ownership: 0.131%Beck Bode LLCBought 27,272 shares on 5/22/2024Ownership: 0.016%Burney Co.Sold 153,634 shares on 5/22/2024Ownership: 0.014%Tidal Investments LLCBought 16,282 shares on 5/17/2024Ownership: 0.010%View All Insider TransactionsView All Institutional Transactions ALKS Stock Analysis - Frequently Asked Questions How have ALKS shares performed this year? Alkermes' stock was trading at $27.74 at the beginning of 2024. Since then, ALKS shares have decreased by 12.4% and is now trading at $24.29. View the best growth stocks for 2024 here. How were Alkermes' earnings last quarter? Alkermes plc (NASDAQ:ALKS) posted its earnings results on Wednesday, May, 1st. The company reported $0.43 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.58 by $0.15. The firm's quarterly revenue was up 21.8% on a year-over-year basis. Is Alkermes doing a stock buyback? Alkermes' Board of Directors approved a share buyback plan on Thursday, February 15th 2024, which permits the company to repurchase $400,000,000 in shares, according to EventVestor. This means that the company could reacquire up to 8.2% of its shares through open market purchases. Shares buyback plans are usually a sign that the company's leadership believes its stock is undervalued. What is Richard F. Pops' approval rating as Alkermes' CEO? 119 employees have rated Alkermes Chief Executive Officer Richard F. Pops on Glassdoor.com. Richard F. Pops has an approval rating of 84% among the company's employees. Does Alkermes have any subsidiaries? Alkermes subsidiaries include these companies: Rodin Therapeutics. Who are Alkermes' major shareholders? Alkermes' top institutional investors include GAMMA Investing LLC. Insiders that own company stock include Richard F Pops, Michael J Landine, Shane Cooke, David Joseph Gaffin, Blair Curtis Jackson, Christian Todd Nichols, Nancy Wysenski, Cato T Laurencin, Emily Peterson Alva and Craig C Hopkinson. View institutional ownership trends. How do I buy shares of Alkermes? Shares of ALKS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Alkermes own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alkermes investors own include Gilead Sciences (GILD), Netflix (NFLX), Pfizer (PFE), NVIDIA (NVDA), AbbVie (ABBV), Starbucks (SBUX) and This page (NASDAQ:ALKS) was last updated on 7/6/2024 by MarketBeat.com Staff From Our PartnersWhy Conservative Americans Are Turning to Gold in 2024Welcome to the financial rollercoaster of 2024, where inflation is relentless, stock markets are inflated, and...All American Assets | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Weiss Ratings | SponsoredGrab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alkermes plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Alkermes With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALKS Stock Alerts